Myasthenia gravis

Dr Henry Knipe et al.

Myasthenia gravis (MG) is the most common neuromuscular junction disease, and presents with increasing fatigue brought on by exertion. 

Incidence is estimated at 15-20 per 100,000 1,2. Females are more affected (3:1) under the age of 40, but males are more affected over the age of 50 2

Most patients present with ocular symptoms (e.g. diplopia), with the majority (80%) proceeding to experience generalised weakness 1

Myasthenia gravis is an autoimmune disease with anti-AChR and/or anti-MuSK antibodies affecting postsynaptic acetylcholine receptors or muscle specific tyrosine-kinase, respectively 1,2

Along with corticosteroids, immunosuppressant drugs (e.g. cyclosporin, cyclophosphamide, azathioprine) have tradtionally been the mainstays of disease-modifying therapy for the disease. Mycophenolate mofetil (MMF) has been traditionally used to treat myasthenia gravis 6. Other treatments include orally active cholinesterase inhibitors such as Mestinon TM (pyridostigmine bromide). 

Share article

Article information

rID: 41664
Section: Pathology
Synonyms or Alternate Spellings:
  • Myasthenia gravis (MG)

Support Radiopaedia and see fewer ads

Cases and figures

  • Drag
    Case 1: with thymoma
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.